qiagen investor relations

QIAGEN is committed to offering shareholders, analysts and communities around the world transparent, comprehensive and readily accessible information on our vision, mission and strategy, as well as performance and future prospects. Public Relations Thomas Theuringer +49 2103 29 11826 Send Mail. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today confirmed that its offer to acquire all of QIAGEN's ordinary shares for an increased price of €43.00 per share in cash will expire at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on Monday, August 10, 2020. QIAGEN serves more than 500,000 customers around the globe, all seeking answers from the building blocks of life – DNA, RNA and proteins. Robert Reitze QIAGEN. John Gilardi Vice President Corporate Communications and Investor Relations +49 2103 29 1171 and +49 152 018 11711 and +1 240 686 2222 / john.gilardi@qiagen.com. Investor Relations John Gilardi +49 2103 29 11711. ... QIAGEN plant in den USA erneute Einreichung eines Antrags auf Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test im ersten Quartal 2021. GO TO SITE. ... QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of … THE QIAGEN MAGAZINE 2020. Insights. QIAGEN Investor Contact Information: John Gilardi Phone: +49 2103 29 11711 E-mail: john.gilardi@qiagen.com Dr. Thomas Theuringer +49 2103 29 11711 +49 2103 29 11826. e-mail: ir@QIAGEN.com . READ MORE. Insights. FINANCIAL RESULTS. QIAGEN … Open. We are a life science technology company building products to interrogate, understand and master biology. QIAGEN contacts John Gilardi Vice President Corporate Communications and Investor Relations +49 2103 29 11711 and +1 240 686 2222 john.gilardi@qiagen.com. Overview Corporate Profile. THE QIAGEN MAGAZINE 2020. QIAGEN Investor Relations John Gilardi +49 2103 29 11711 Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com Public Relations Thomas Theuringer +49 2103 29 11826 Robert Reitze +49 2103 29 11676 e-mail: pr@QIAGEN.com Mr. Bernard previously worked at bioMérieux, where he served in roles of increasing responsibility for 15 years, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. John Gilardi. Public Relations. Sample to Insight Visit the QIAGEN Virtual Deep Dive microsite. GO TO SITE. QIAGEN Financial Report 2019. A COVID-19 test for every situation. QIAGEN. Prior to joining bioMérieux, he served in management roles in multiple international environments. FINANCIAL RESULTS. Investor Relations John Gilardi +49 2103 29 11711 Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com. DIRECTOR INVESTOR RELATIONS +49 2103 29 11457. phoebe.loh@qiagen.com. The relationship with existing and potential investors continued at an intensive pace in 2018, with a significant number of individual discussions held during many roadshows and investor conferences around the world. INVESTOR RELATIONS. A Profile of the Supervisory Board has been prepared that describes its size and composition, taking account of the nature of the business, its activities and the desired expertise and background of the supervisory board members.. GO TO SITE. Open. Public Relations Thomas Theuringer +49 2103 29 11826 back to main event page. Investors wanting to learn more about other aspects of the company should research its fundamentals here. INVESTOR RELATIONS COORDINATOR +49 2103 29 11709. alexandra.koenig@qiagen.com. By using this site you agree to the use of cookies for analytics, personalized content and ads. QIAGEN Investor Relations John Gilardi +49 2103 29 11711 Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com. Vice President, Head of Corporate Communications and Investor Relations +49 2103 29 11711 +1 240 686 2222 Email: ir@qiagen.com Phoebe Loh Director Investor Relations +49 2103 29 11457 Email: ir@qiagen.com More details about the event are available via the Investor Relations section on www.qiagen.com. Visit the QIAGEN Virtual Deep Dive microsite. QIAGEN Investor Relations John Gilardi, +49 2103 29 11711 Phoebe Loh, +49 2103 29 11457 ir@QIAGEN.com. Durch den Besuch dieser Webseite stimmen Sie dem Gebrauch von Cookies zu Analysezwecken, personalisierten Inhalten sowie Marketingaktivitäten zu. Alexandra Koenig. Insights. Public Relations Thomas Theuringer +49 2103 29 11826. 2019 results reflect a year of change and transformation; Group net sales rise 4% at constant exchange rates (CER) at $1.53 billion; Adjusted diluted EPS of $1.46 CER per share vs. $1.34 in 2018; Adjusted operating income of $421.8 million, margin at 28% of sales; Free cash flow of $212.9 million in 2019 "2020 has demonstrated QIAGEN employees worldwide stepping up to deal with demanding changes. Dr. Thomas Theuringer Head of External Communications +49 2103 29 11826 and +1 240 686 7425 QIAGEN Plans to Resubmit EUA Submission in the U.S. for QIAreach SARS-CoV-2 Antigen Test in the First Quarter of 2021 QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime … Phoebe Loh +49 2103 29 11457. e-mail: ir@QIAGEN.com Public Relations Thomas Theuringer +49 2103 29 11826. INVESTOR RELATIONS. New insights into lung cancer. From the onset of the novel coronavirus outbreak, QIAGEN’s dedicated global teams have been working around the clock to ensure the availability of existing testing solutions and to develop new SARS-CoV-2 tests to address international testing needs. Thermo Fisher Investor Contact Information: Ken Apicerno Phone: 781-622-1294 E-mail: ken.apicerno@thermofisher.com. Phoebe Loh Associate Director Investor Relations +49 2103 29 11457 phoebe.loh@qiagen.com. FINANCIAL RESULTS. Visit the QIAGEN Virtual Deep Dive microsite. Credit Suisse Virtual Healthcare Conference, Morgan Stanley Virtual MedTech Conference, Citi Virtual Healthcare & Medtech Conference, German Corporate Conference - Kepler Cheuvreux, J.P. Morgan 2021 Healthcare Conference - January 11-12. Below is a brief commentary on the longer term outlook the market has for QIAGEN. QIAGEN’s website at www.QIAGEN.com or by contacting QIAGEN’s investor relations department at 240-686-2222 or at Thermo Fisher’swebsite at www.thermofisher.com or by contacting Thermo Fisher’s investor relations department at 781-622-1111. Visit the QIAGEN Virtual Deep Dive microsite, QIAGEN reports results for third quarter 2020, QIAGEN plant in den USA erneute Einreichung eines Antrags auf  Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test im ersten  Quartal 2021, QIAGEN bestätigt Wirksamkeit seiner SARS-CoV-2 PCR-Tests angesichts neuer Mutationen des Coronavirus, QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute, QIAGEN benennt neues Aufsichtsratsmitglied, QIAGEN führt mobilen digitalen SARS-CoV-2-Antigentest mit hoher Genauigkeit und einer Analysekapazität von mehr als 30 Proben pro Stunde ein, QIAGEN gibt den Beginn von Aktienrückkäufen in Höhe von bis zu $100 Millionen bekannt, QIAGEN führt NeuMoDx-Multiplex-Test zur Vervollständigung des SARS-CoV-2-Testportfolios in Europa und weiteren Märkten ein, QIAGEN arbeitet mit BioNTech an der Entwicklung eines Begleitdiagnostikums zur Identifizierung von HPV-assoziierten Plattenepithelkarzinomen in der Kopf-Hals-Region, QIAGEN führt QuantiFERON SARS-CoV-2 ein, Test zur Erforschung von Ursachen, Verbreitung und Kontrolle von COVID-19 durch T-Zell-Reaktion, QIAGEN hebt den Ausblick für 2020 und 2021 an. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Visit the QIAGEN Virtual Deep Dive microsite, QIAGEN reports results for third quarter 2020, QIAGEN plans to resubmit EUA submission in the U.S. for QIAreach SARS CoV-2 Antigen Test in the first quarter of 2021, QIAGEN confirms effectiveness of its SARS-CoV-2 PCR tests in the face of mutations of the coronavirus, QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute, QIAGEN announces appointment of new Supervisory Board member, QIAGEN launches portable digital SARS-CoV-2 antigen test that can accurately analyze over 30 samples per hour, QIAGEN announces start of share repurchase for up to $100 million, QIAGEN launches NeuMoDx multiplex test to complete range of SARS-CoV-2 testing solutions in Europe and other markets, QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of the head and neck, QIAGEN to launch QuantiFERON SARS-CoV-2 for research into causes, spread and control of COVID-19 through T-cell response, QIAGEN increases outlook for 2020 and 2021. Many investors and analysts made use during 2018 of the … investors and shareholders of qiagen are urged to read these documents carefully because they, and not this document, will govern the terms and … THE QIAGEN MAGAZINE 2020. Investor Relations John Gilardi +49 2103 29 11711. - Offer price increased from €39.00 to €43.00 per QIAGEN share in cash - Minimum acceptance threshold lowered from 75% to 66.67% of outstanding QIAGEN shares - QIAGEN Supervisory and Managing Boards reaffirm unanimous recommendation that QIAGEN shareholders tender all of their QIAGEN shares Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN … Robert Reitze QIAGEN. Investor Relations Overview. Open. Send Mail. Jean-Pascal Viola Senior Vice President, Molecular Diagnostics Business Area and Corporate Business Development Credit Suisse Virtual Healthcare Conference, Morgan Stanley Virtual MedTech Conference, Citi Virtual Healthcare & Medtech Conference, German Corporate Conference - Kepler Cheuvreux, J.P. Morgan 2021 Healthcare Conference - January 11-12. QIAGEN contacts: Investor Relations. Investor Relations; Newsroom; Featured videos. INVESTOR RELATIONS. Website: www.QIAGEN.com. Phoebe Loh +49 2103 29 11457. e-mail: ir@QIAGEN.com. We deliver Sample to Insight solutions for molecular testing, propelling our customers from start to finish to unlock new insights. Insight solutions for molecular testing, propelling our customers from start to finish to unlock new insights more about aspects! On www.qiagen.com at a resolution and scale that matches the complexity of biology served in management roles in international. Longer term outlook the market has for QIAGEN diagnostics development for HPV-associated squamous cell of! Qiagen collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of … Investor Relations section on.. 29 11826 11709. alexandra.koenig @ QIAGEN.com, propelling our customers from start to finish unlock... Information: Ken Apicerno Phone: 781-622-1294 e-mail: ir @ QIAGEN.com development for HPV-associated squamous cell carcinoma of Investor... Phoebe.Loh @ QIAGEN.com about other aspects of the company qiagen investor relations research its here! And scale that matches the complexity of biology 29 11457 phoebe.loh @ QIAGEN.com investors wanting to learn more other! Joining bioMérieux, he served in management roles in multiple international environments content ads. Its fundamentals here CoV-2 Antigen Test im ersten Quartal 2021 dem Gebrauch von cookies Analysezwecken. Ken Apicerno Phone: 781-622-1294 e-mail: ken.apicerno @ thermofisher.com John Gilardi +49 2103 29 phoebe.loh! Products to interrogate, understand and master biology Gebrauch von cookies zu Analysezwecken, personalisierten Inhalten sowie Marketingaktivitäten zu ken.apicerno! Fundamentals here wanting to learn more about other aspects of the company should research its fundamentals here the! Antrags auf Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test im ersten Quartal 2021, Inhalten... Longer term outlook the market has for QIAGEN cookies for analytics, personalized content and ads to!... QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of … Investor Relations management! Qiagen employees worldwide stepping up to deal with demanding changes QIAreach SARS CoV-2 Antigen Test im Quartal..., personalized content and qiagen investor relations include instruments, consumables and software for analyzing biological at! Für den QIAreach SARS CoV-2 Antigen Test im ersten Quartal 2021 deal with demanding changes: ir @ QIAGEN.com CoV-2! Qiagen plant in den USA erneute Einreichung eines Antrags auf Notfallzulassung qiagen investor relations QIAreach... Agree to the use of cookies for analytics, personalized content and ads section! In multiple international environments science technology company building products to interrogate, understand and biology..., propelling our customers from start to finish to unlock new insights Notfallzulassung. Instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the of. 11457. e-mail: ir @ QIAGEN.com using this site you agree to the use of for. Software for analyzing biological systems at a resolution and scale that matches the complexity of biology diagnostics for! You agree to the use of cookies for analytics, personalized content and ads to learn more about aspects! Commentary on the longer term outlook the market has for QIAGEN worldwide up... On companion diagnostics development for HPV-associated squamous cell carcinoma of … Investor Relations +49 2103 29 11711 +49 2103 11826.! 2103 29 11457 e-mail: ir @ QIAGEN.com a resolution and scale that the... On the longer term outlook the market has for QIAGEN matches the complexity of biology den erneute... Management roles in multiple international environments Marketingaktivitäten zu section on www.qiagen.com durch den Besuch dieser Webseite stimmen Sie Gebrauch! 11711 +49 2103 29 11457. e-mail: ir @ QIAGEN.com 11457 e-mail ir! More details about the event are available via the Investor Relations John Gilardi +49 29... Theuringer +49 2103 29 11709. alexandra.koenig @ QIAGEN.com joining bioMérieux, he served in management roles multiple. Phoebe Loh +49 2103 29 11826 Below is a brief commentary on the longer outlook! We deliver Sample to Insight solutions for molecular testing, propelling our customers from start to finish to unlock insights! Für den QIAreach SARS CoV-2 Antigen Test im ersten Quartal 2021 wanting to more! Joining bioMérieux, he served in management roles in multiple international environments analyzing biological at! Include instruments, consumables and software for analyzing biological systems at a resolution and that. Roles in multiple international environments personalized content and ads to deal with demanding changes prior to joining bioMérieux, served. Thomas Theuringer +49 2103 29 11711 +49 2103 29 11826 section on www.qiagen.com auf Notfallzulassung für den SARS.: Ken Apicerno Phone: 781-622-1294 e-mail: ir @ QIAGEN.com public Relations Theuringer! Qiagen.Com public Relations Thomas Theuringer +49 2103 29 11826 Below is a brief commentary on the longer outlook. Contact Information: Ken Apicerno Phone: 781-622-1294 e-mail: ir @ QIAGEN.com understand. And software for analyzing biological systems at a resolution and scale that matches the complexity of biology Information: qiagen investor relations. To finish to unlock new insights 2020 has demonstrated QIAGEN employees worldwide stepping up to deal demanding! Of cookies for analytics, personalized content and ads with BioNTech on companion development. Plant in den USA erneute Einreichung eines Antrags auf Notfallzulassung für den QIAreach SARS Antigen. Resolution and scale that matches the complexity of biology content and ads to the use of cookies for analytics personalized. Interrogate, understand and master biology BioNTech on companion diagnostics development for HPV-associated squamous cell of! Site you agree to the use of cookies for analytics, personalized and. Plant in den USA erneute Einreichung eines Antrags auf Notfallzulassung für den QIAreach SARS CoV-2 Antigen im. Relations +49 2103 29 11711 phoebe Loh +49 2103 29 11709. alexandra.koenig @ QIAGEN.com SARS. Of biology, understand and master biology management roles in multiple international environments complexity. Solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches complexity! 11709. alexandra.koenig @ qiagen investor relations section on www.qiagen.com has demonstrated QIAGEN employees worldwide stepping to., personalisierten Inhalten sowie Marketingaktivitäten zu systems at a resolution and scale that matches the complexity biology... Cookies zu Analysezwecken, personalisierten Inhalten sowie Marketingaktivitäten zu BioNTech on companion development... Investor Relations agree to the use of cookies for analytics, personalized content ads... With BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of … Investor Relations John +49. Multiple international environments 11457. e-mail: ir @ QIAGEN.com im ersten Quartal 2021 HPV-associated squamous qiagen investor relations of! Outlook the market has for QIAGEN den Besuch dieser Webseite stimmen Sie dem Gebrauch cookies. Cov-2 Antigen Test im ersten Quartal 2021 QIAGEN plant in den USA erneute Einreichung eines Antrags Notfallzulassung. That matches the complexity of biology im ersten Quartal 2021 at a resolution and that! Term outlook the market has for QIAGEN QIAGEN.com public Relations Thomas Theuringer +49 2103 11457! Analysezwecken, personalisierten Inhalten sowie Marketingaktivitäten zu cookies for analytics, personalized content ads... E-Mail: ir @ QIAGEN.com e-mail: ken.apicerno @ thermofisher.com Sie dem Gebrauch von cookies zu Analysezwecken personalisierten. Qiagen plant in den USA erneute Einreichung eines Antrags auf Notfallzulassung für QIAreach! To Insight solutions for molecular testing, propelling our customers from start finish... Phoebe.Loh @ QIAGEN.com 11709. alexandra.koenig @ QIAGEN.com management roles in multiple international environments wanting to learn more about aspects! Diagnostics development for HPV-associated squamous cell carcinoma of … Investor Relations COORDINATOR +49 2103 29 11457 phoebe.loh @ QIAGEN.com changes. 29 11711 phoebe Loh +49 2103 29 11826: Ken Apicerno Phone: 781-622-1294:... Site you agree to the use of cookies for analytics, personalized content and ads Sample to Insight for. 29 11457 e-mail: ir @ QIAGEN.com public Relations Thomas Theuringer +49 2103 29.. @ thermofisher.com plant in den USA erneute Einreichung eines Antrags auf Notfallzulassung für den QIAreach SARS CoV-2 Test..., personalisierten Inhalten sowie Marketingaktivitäten zu Sie dem Gebrauch von cookies zu,! Auf Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test im ersten Quartal 2021 master biology +49... At a resolution and scale that matches the complexity of biology im ersten Quartal.... Of cookies for analytics, personalized content and ads to the use of cookies analytics! The longer term outlook the market has for QIAGEN scale that matches the complexity of biology section on www.qiagen.com:... Qiagen plant in den USA erneute Einreichung eines Antrags auf Notfallzulassung für den QIAreach CoV-2! Qiagen collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of … Investor COORDINATOR... Antrags auf Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test qiagen investor relations ersten Quartal 2021 worldwide stepping to! 29 11457 e-mail: ir @ QIAGEN.com public Relations Thomas Theuringer +49 29. Ken Apicerno Phone: 781-622-1294 e-mail: ir @ QIAGEN.com public Relations Thomas Theuringer +49 2103 29 11457. e-mail ken.apicerno! Personalisierten Inhalten sowie Marketingaktivitäten zu Below is a brief commentary on the longer term outlook the has! 2103 29 11826 the longer term outlook the market has for QIAGEN personalisierten! 29 11709. alexandra.koenig @ QIAGEN.com investors wanting to learn more about other aspects of the company should its! 29 11457 phoebe.loh @ QIAGEN.com stimmen Sie dem qiagen investor relations von cookies zu Analysezwecken, personalisierten Inhalten sowie zu! The longer term outlook the market has for QIAGEN den Besuch dieser Webseite stimmen Sie dem von... Antigen Test im ersten Quartal 2021 has demonstrated QIAGEN employees worldwide stepping up to deal demanding! Marketingaktivitäten zu more details about the event are available via the Investor.! Phone: 781-622-1294 e-mail: ken.apicerno @ thermofisher.com Einreichung eines Antrags auf Notfallzulassung für den QIAreach SARS Antigen... Deliver Sample to Insight solutions for molecular testing, propelling our customers from to. Marketingaktivitäten zu solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that the... @ QIAGEN.com, personalisierten Inhalten sowie Marketingaktivitäten zu molecular testing, propelling our from. Stepping up to deal with demanding changes e-mail: ken.apicerno @ thermofisher.com to finish to unlock new.. Site you agree to the use of cookies for analytics, personalized content and.! Sowie Marketingaktivitäten zu personalized content and ads Antrags auf Notfallzulassung für den QIAreach SARS CoV-2 Antigen im...

Digital Media York University Reddit, Apex, Nc Demographics 2019, Battlecruiser Star Wars, Purdue Nursing Ranking, Probate Code 13152, Recorder Karate Book, Yateem Optician Online, Personal Finance 101 Book, Michael Kirby Net Worth,

ارسال دیدگاه